cariprazine vs paliperidone
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of cariprazine and paliperidone. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Vraylar
Invega
Vraylar is a medicine used to treat certain mental health conditions. It can help with schizophrenia, bipolar disorder, and major depressive disorder.
Paliperidone extended-release tablets, also known as Invega, are a type of antipsychotic medicine. It helps manage symptoms of certain mental disorders.
Vraylar can treat schizophrenia in adults and kids 13 and older. It also treats manic or mixed episodes of bipolar I disorder in adults and kids 10 and older. In adults, Vraylar treats the depressive episodes of bipolar I disorder. Vraylar can also be used with antidepressants to treat major depressive disorder in adults.
This medicine is used to treat schizophrenia in adults and teens (12-17 years old). It can also treat schizoaffective disorder in adults, either alone or with other medicines like mood stabilizers or antidepressants. Schizophrenia can cause hallucinations, delusions, and confused thinking. Schizoaffective disorder includes symptoms of both schizophrenia and mood disorders.
Vraylar affects certain chemicals in the brain. These chemicals are called neurotransmitters. By changing the balance of these chemicals, Vraylar can help reduce symptoms of mental health conditions.
Paliperidone affects certain chemicals in the brain. These chemicals, like dopamine, can become unbalanced in people with schizophrenia and schizoaffective disorder. By acting on these chemicals, paliperidone helps to reduce symptoms.
- • Problems with muscle movement
- • Feeling restless
- • Upset stomach
- • Throwing up
- • Feeling sleepy
- • Extrapyramidal symptoms (movement problems)
- • Fast heart rate
- • Feeling restless and unable to sit still
- • Sleepiness
- • Indigestion
- Weight Increased 441
- Akathisia 395
- Anxiety 354
- Tardive Dyskinesia 347
- Nausea 331
- Injury 4,331
- Gynaecomastia 3,664
- Abnormal Weight Gain 1,660
- Weight Increased 1,361
- Hyperprolactinaemia 1,255
Vraylar may increase the risk of death in older adults with dementia-related psychosis. Vraylar and antidepressants can increase suicidal thoughts and behaviors in children, teens, and young adults. Tell your doctor right away if you have thoughts of harming yourself.
This medicine has a boxed warning. It may increase the risk of death in elderly patients with dementia-related psychosis. Paliperidone is not approved to treat this condition.
Vraylar may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. There is a pregnancy registry for women who take Vraylar during pregnancy; you can contact them at 1-866-961-2388.
If you are pregnant or plan to become pregnant, talk to your doctor. Babies born to mothers who use this medicine in the last 3 months of pregnancy may have withdrawal symptoms or movement problems after birth. There is a pregnancy registry to monitor outcomes in women exposed to atypical antipsychotics during pregnancy. You can contact the registry at 1-866-961-2388.
Also Compare, Nearby Drugs
Compare cariprazine with
Compare paliperidone with
How to Read This cariprazine vs paliperidone Comparison
cariprazine is classified in the Atypical Antipsychotic drug class, while paliperidone sits within the Atypical Antipsychotic class. Because both drugs share the same classification, they are often considered interchangeable in theory, but clinical outcomes rarely track that cleanly. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, cariprazine has 1,868 submissions while paliperidone has 12,271. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for cariprazine or paliperidone.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.